Summary of Clinical Use

Carbenoxolone is not approved by the US FDA or EMA. Its use is authorised by other national approval agencies, where it is used for the treatment of peptic, esophageal and oral ulceration and inflammation.

Mechanism Of Action and Pharmacodynamic Effects

Carbenoxolone inhibits 11β-hydroxysteroid dehydrogenase type 1, and through this mechanism increases levels of the active glucocorticoid, cortisol. Cortisol-induced activation of the glucocorticoid receptor produces an antiinflammatory response.